Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 17/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 17/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 17/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 17/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 17/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 17/20 | 0.57 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021467 | 0.93 | PSEN1 (0.59) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021343 | 0.91 | APP (0.59) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021399 | 0.90 | PSEN1 (0.53) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021376 | 0.90 | APP (0.60) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021382 | 0.90 | PSEN1 (0.53) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021397 | 0.89 | PSEN1 (0.56) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021478 | 0.89 | PSEN1 (0.60) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021392 | 0.88 | APP (0.59) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021339 | 0.87 | PSEN1 (0.61) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20021488 | 0.87 | PSEN1 (0.57) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, APP | APP 3/4885PSEN1 4/4885PSEN2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.